title: Usefulness of artificial liver support for pretransplant patients with fulminant hepatic failure.
abstract: This study assessed the usefulness of artificial liver support (ALS) for pretransplant patients with fulminant hepatic failure (FHF). Five patients (age 14 to 52 years, 3 men and 2 women) with FHF who were being prepared for living donor liver transplantation (LDLTx) were enrolled in this study. ALS included plasma exchange, using 40 to 50 units of fresh frozen plasma per session, and high-flow hemodiafiltration, using a high-performance polysulfone membrane. Variables such as circulatory and respiratory function, coma grade, and neurologic disorders were evaluated. Although systolic and diastolic blood pressures showed no statistical differences between pre-ALS and post-ALS, the difference in heart rates was statistically significant. After ALS initiation in the pre-LDLTx period, one of the three patients who needed mechanical ventilation was weaned from it. After LDLTx, all patients recovered neurologically; no neurologic disorder was observed. These results suggested that ALS could predict neurologic status after LDLTx. The difference in coma grades also achieved statistical significance. Our study indicates that short-term ALS is useful for improving circulatory and respiratory function prior to liver transplantation, as well as for predicting posttransplantation neurologic status. Although some patients recover by ALS alone, the survival rate of ALS-only patients is less than 50%. ALS prolongs intensive treatment, thus increasing both the risk of infection and the medical costs. Further investigation to determine a precise marker for liver regeneration will be needed to establish a consensus on the indications for long-term ALS. We conclude that ALS is useful to improve circulatory and respiratory functions among pretransplant patients, and to predict neurologic status after LDLTx.
authors.affiliation: Hepato-Biliary-Pancreatic Surgery and Liver Transplantation Division, Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Yokohama, Japan. Sekido@med.yokohama-cu.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Sekido
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: K
authors.initials: K
authors.lastname: Takeda
authors.forename: M
authors.initials: M
authors.lastname: Ueda
authors.forename: D
authors.initials: D
authors.lastname: Morioka
authors.forename: T
authors.initials: T
authors.lastname: Kubota
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: I
authors.initials: I
authors.lastname: Endo
authors.forename: S
authors.initials: S
authors.lastname: Togo
authors.forename: H
authors.initials: H
authors.lastname: Shimada
mesh_terms: D000293:Adolescent; D000328:Adult; D001794:Blood Pressure; D005260:Female; D006501:Hepatic Encephalopathy / Q000517:prevention & control; D006801:Humans; D017114:Liver Failure, Acute / Q000628:therapy*; D016031:Liver Transplantation; D019164:Liver, Artificial; D008875:Middle Aged; D018579:Patient Selection; D016896:Treatment Outcome